Stocks rallied strongly Wednesday after Fed chief Jerome Powell hinted at slower Fed rate hikes. Watch out for day 2 reactions Read More...
Benzinga
Pfizer/BioNTech Start Ohase 2 Trial For COVID-19 Vaccine Against Omicron Subvariant
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. Related: BioNTech, Pfizer File For Clear
Add Comment